Clinical Trial Update: Allogenic Haematopoietic Cell Transplantation for Patients With Refractory "Triple Negative" Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating allogeneic hematopoietic cell transplantation for patients with refractory triple-negative breast cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Snippet

Sponsor: European Institute of Oncology | Conditions: Breast Cancer | Phase 2 | Status: TERMINATED